Erratum

This article refers to:

Lenalidomide in multiple myeloma: current role and future directions

In the Drug Evaluation ‘Lenalidomide in multiple myeloma: current role and future directions’ by Zeldis et al. (Expert Opin. Pharmacother. (2010) 11(5):829-842), the last line on page 830 should have appeared as follows:

Lenalidomide is 50 - 2000 times more potent than thalidomide with most of these activities. (For chemical structures of lenalidomide and thalidomide, see Figure 1.)

In addition, on page 834, Figure 1 should have appeared as follows:

The publishers and authors apologise for any inconvenience caused.